A Phase 2/3, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Trial Profile

A Phase 2/3, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 05 Apr 2017 Primary endpoint (Progression-free Survival) has been met.
    • 05 Apr 2017 Results assessing efficacy (n=102) and safety (n=109) in overall population and DLBCL subtypes (GCB and non GCB), published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 16 Jun 2016 The trial was completed in Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top